Alan Walts Ph.D

Alan Walts Ph.D General Information

Biography

Dr. Alan Walts serves as a Board Observer at Arrakis Therapeutics. He also serves as Executive Chairman at PIC Therapeutics. He also serves as Executive Chairman at Artax Biopharma. He also serves as a Board Observer at Aura Biosciences. Previously he held the position of Executive Chairman at the company. He is a Co-Founder and serves as a Board Member at X4 Pharmaceuticals. He also served as Executive Chairman at Zikani Therapeutics. He serves as an Advisor at ALS Investment Fund. He serves as a Venture Partner at Advent Life Sciences. He joined the Advent Life Sciences team in 2014 and brings 27 years of industry experience in corporate venture capital, business development, research and development, and general management at Genzyme Corporation. In addition to his role at Advent, he currently works as a business advisor to Genzyme's former Chairman and Chief Executive Officer, Henri Termeer, and as a Board Member and Advisor to various life science companies. He most recently managed Genzyme's corporate venture fund, Genzyme Ventures (now Sanofi-Genzyme BioVentures), where he was responsible for identifying and closing several new investments and for managing a portfolio of direct and LP investments. He earlier led business and corporate development activities in Genzyme's Therapeutics business, where he initiated and executed several transactions and new business initiatives that led to several innovative marketed products. His roles at Genzyme also included President of Genzyme Pharmaceuticals and head of chemistry and biopolymer research. He received a Ph.D. in chemistry from MIT in 1985, carried out post-doctoral research in biochemistry at MIT with Professor Christopher Walsh, and completed the Executive Program for Management Development at Harvard Business School in 1993. He holds degrees from the Massachusetts Institute of Technology (MIT). He is a Co-Founder and serves as Executive Chairman at AlphaRose Therapeutics.